Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: A longitudinal study
Abstract Changes in brain-derived neurotrophic factor (BDNF) level are implicated in the pathophysiology of cognitive decline in depression and neurodegenerative disorders in older adults. We aimed to evaluate the longitudinal association over two years between BDNF and persistent cognitive decline...
Gespeichert in:
| Veröffentlicht in: | Journal of psychiatric research 2014-02, Vol.49, p.96-101 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101 |
|---|---|
| container_issue | |
| container_start_page | 96 |
| container_title | Journal of psychiatric research |
| container_volume | 49 |
| creator | Diniz, Breno Satler Reynolds, Charles F Begley, Amy Dew, Mary Amanda Anderson, Stewart J Lotrich, Francis Erickson, Kirk I Lopez, Oscar Aizenstein, Howard Sibille, Etienne L Butters, Meryl A |
| description | Abstract Changes in brain-derived neurotrophic factor (BDNF) level are implicated in the pathophysiology of cognitive decline in depression and neurodegenerative disorders in older adults. We aimed to evaluate the longitudinal association over two years between BDNF and persistent cognitive decline in individuals with remitted late-life depression and Mild Cognitive Impairment (LLD + MCI) compared to either individuals with remitted LLD and no cognitive decline (LLD + NCD) or never-depressed, cognitively normal, elderly control participants. We additionally evaluated the effect of double-blind, placebo-controlled donepezil treatment on BDNF levels in all of the remitted LLD participants (across the levels of cognitive function). We included 160 elderly participants in this study (72 LLD + NCD, 55 LLD + MCI and 33 never-depressed cognitively normal elderly participants). At the same visits, cognitive assessments were conducted and blood sampling to determine serum BDNF levels were collected at baseline assessment and after one and two years of follow-up. We utilized repeated measure, mixed effect models to assess: (1) the effects of diagnosis (LLD + MCI, LLD + NCD, and controls), time, and their interaction on BDNF levels; and (2) the effects of donepezil treatment (donepezil vs. placebo), time, baseline diagnosis (LLD + MCI vs. LLD + NCD), and interactions between these contrasts on BDNF levels. We found a significant effect of time on BDNF level ( p = 0.02) and a significant decline in BDNF levels over 2 years of follow-up in participants with LLD + MCI ( p = 0.004) and controls ( p = 0.04). We found no effect of donepezil treatment on BDNF level. The present results suggest that aging is an important factor related to decline in BDNF level. Clinicaltrials.gov Identifier: NCT00177671. |
| doi_str_mv | 10.1016/j.jpsychires.2013.11.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3921964</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0022395613003439</els_id><sourcerecordid>1540234869</sourcerecordid><originalsourceid>FETCH-LOGICAL-c696t-245548d6b703b301ea44365b0efc4c3261fb25b0231f0ec041f366e570915fd93</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhiMEoqXwF5AvSFyy-CvOhkOltuJLqsQBOFuOM9mdxbGDnay0h_53HO3SAqeebMvPvPOO3ikKwuiKUabe7Va7MR3sFiOkFadMrBhbUSqfFOdsXTclE3XztDinlPNSNJU6K16ktKOU1pzJ58UZl7yhQtXnxd11NOjLDiLuoSMe5himGMYtWtIbO4VIHOzBJYKeODNB6bAH0sGYWycMnhjfERuGEFvsyIBueW08TlmP4DAajAP46T25Ii74DU5zh944kvLl8LJ41huX4NXpvCh-fPzw_eZzefv105ebq9vSqkZNJZdVJdedamsqWkEZGCmFqloKvZVWcMX6lucnF6ynYKlkvVAKqpo2rOq7RlwUl0fdcW4H6Gw2FI3TY8TBxIMOBvW_Px63ehP2WjScNUpmgbcngRh-zZAmPWCy4JzxEOakWSVZUyvVVI9Bs1G5Vout9RG1MaQUob93xKhegtY7_RC0XoLWjOkcdC59_fdE94V_ks3AmxNgkjWuj8ZbTA_cmirJqcrc9ZHLGcMeIepkEbyFLve0k-4CPsbN5X8i1qHH3PcnHCDtwhxz5nl2nbim-tuymMteMkGpkKIRvwFGieOd</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1540234869</pqid></control><display><type>article</type><title>Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: A longitudinal study</title><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Diniz, Breno Satler ; Reynolds, Charles F ; Begley, Amy ; Dew, Mary Amanda ; Anderson, Stewart J ; Lotrich, Francis ; Erickson, Kirk I ; Lopez, Oscar ; Aizenstein, Howard ; Sibille, Etienne L ; Butters, Meryl A</creator><creatorcontrib>Diniz, Breno Satler ; Reynolds, Charles F ; Begley, Amy ; Dew, Mary Amanda ; Anderson, Stewart J ; Lotrich, Francis ; Erickson, Kirk I ; Lopez, Oscar ; Aizenstein, Howard ; Sibille, Etienne L ; Butters, Meryl A</creatorcontrib><description>Abstract Changes in brain-derived neurotrophic factor (BDNF) level are implicated in the pathophysiology of cognitive decline in depression and neurodegenerative disorders in older adults. We aimed to evaluate the longitudinal association over two years between BDNF and persistent cognitive decline in individuals with remitted late-life depression and Mild Cognitive Impairment (LLD + MCI) compared to either individuals with remitted LLD and no cognitive decline (LLD + NCD) or never-depressed, cognitively normal, elderly control participants. We additionally evaluated the effect of double-blind, placebo-controlled donepezil treatment on BDNF levels in all of the remitted LLD participants (across the levels of cognitive function). We included 160 elderly participants in this study (72 LLD + NCD, 55 LLD + MCI and 33 never-depressed cognitively normal elderly participants). At the same visits, cognitive assessments were conducted and blood sampling to determine serum BDNF levels were collected at baseline assessment and after one and two years of follow-up. We utilized repeated measure, mixed effect models to assess: (1) the effects of diagnosis (LLD + MCI, LLD + NCD, and controls), time, and their interaction on BDNF levels; and (2) the effects of donepezil treatment (donepezil vs. placebo), time, baseline diagnosis (LLD + MCI vs. LLD + NCD), and interactions between these contrasts on BDNF levels. We found a significant effect of time on BDNF level ( p = 0.02) and a significant decline in BDNF levels over 2 years of follow-up in participants with LLD + MCI ( p = 0.004) and controls ( p = 0.04). We found no effect of donepezil treatment on BDNF level. The present results suggest that aging is an important factor related to decline in BDNF level. Clinicaltrials.gov Identifier: NCT00177671.</description><identifier>ISSN: 0022-3956</identifier><identifier>EISSN: 1879-1379</identifier><identifier>DOI: 10.1016/j.jpsychires.2013.11.004</identifier><identifier>PMID: 24290367</identifier><identifier>CODEN: JPYRA3</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Adult and adolescent clinical studies ; Aged ; Aged, 80 and over ; Antidepressive Agents - therapeutic use ; BDNF ; Biological and medical sciences ; Brain-Derived Neurotrophic Factor - blood ; Cognitive Dysfunction - blood ; Cognitive Dysfunction - drug therapy ; Cognitive Dysfunction - epidemiology ; Cognitive impairment ; Dementia ; Depression ; Depression - drug therapy ; Depression - epidemiology ; Diagnosis ; Donepezil ; Elderly ; Elderly people ; Enzyme-Linked Immunosorbent Assay ; Female ; Geriatrics ; Humans ; Indans - therapeutic use ; Late-life depression ; Linear Models ; Longitudinal Studies ; Male ; Medical sciences ; Mild cognitive impairment ; Miscellaneous ; Mood disorders ; Nervous system ; Pathophysiology ; Piperidines - therapeutic use ; Psychiatry ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Time Factors</subject><ispartof>Journal of psychiatric research, 2014-02, Vol.49, p.96-101</ispartof><rights>Elsevier Ltd</rights><rights>2013 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier Ltd. All rights reserved.</rights><rights>2013 Elsevier Ltd. All rights reserved. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c696t-245548d6b703b301ea44365b0efc4c3261fb25b0231f0ec041f366e570915fd93</citedby><cites>FETCH-LOGICAL-c696t-245548d6b703b301ea44365b0efc4c3261fb25b0231f0ec041f366e570915fd93</cites><orcidid>0000-0003-0653-1905</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022395613003439$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,30977,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28064206$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24290367$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Diniz, Breno Satler</creatorcontrib><creatorcontrib>Reynolds, Charles F</creatorcontrib><creatorcontrib>Begley, Amy</creatorcontrib><creatorcontrib>Dew, Mary Amanda</creatorcontrib><creatorcontrib>Anderson, Stewart J</creatorcontrib><creatorcontrib>Lotrich, Francis</creatorcontrib><creatorcontrib>Erickson, Kirk I</creatorcontrib><creatorcontrib>Lopez, Oscar</creatorcontrib><creatorcontrib>Aizenstein, Howard</creatorcontrib><creatorcontrib>Sibille, Etienne L</creatorcontrib><creatorcontrib>Butters, Meryl A</creatorcontrib><title>Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: A longitudinal study</title><title>Journal of psychiatric research</title><addtitle>J Psychiatr Res</addtitle><description>Abstract Changes in brain-derived neurotrophic factor (BDNF) level are implicated in the pathophysiology of cognitive decline in depression and neurodegenerative disorders in older adults. We aimed to evaluate the longitudinal association over two years between BDNF and persistent cognitive decline in individuals with remitted late-life depression and Mild Cognitive Impairment (LLD + MCI) compared to either individuals with remitted LLD and no cognitive decline (LLD + NCD) or never-depressed, cognitively normal, elderly control participants. We additionally evaluated the effect of double-blind, placebo-controlled donepezil treatment on BDNF levels in all of the remitted LLD participants (across the levels of cognitive function). We included 160 elderly participants in this study (72 LLD + NCD, 55 LLD + MCI and 33 never-depressed cognitively normal elderly participants). At the same visits, cognitive assessments were conducted and blood sampling to determine serum BDNF levels were collected at baseline assessment and after one and two years of follow-up. We utilized repeated measure, mixed effect models to assess: (1) the effects of diagnosis (LLD + MCI, LLD + NCD, and controls), time, and their interaction on BDNF levels; and (2) the effects of donepezil treatment (donepezil vs. placebo), time, baseline diagnosis (LLD + MCI vs. LLD + NCD), and interactions between these contrasts on BDNF levels. We found a significant effect of time on BDNF level ( p = 0.02) and a significant decline in BDNF levels over 2 years of follow-up in participants with LLD + MCI ( p = 0.004) and controls ( p = 0.04). We found no effect of donepezil treatment on BDNF level. The present results suggest that aging is an important factor related to decline in BDNF level. Clinicaltrials.gov Identifier: NCT00177671.</description><subject>Adult and adolescent clinical studies</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>BDNF</subject><subject>Biological and medical sciences</subject><subject>Brain-Derived Neurotrophic Factor - blood</subject><subject>Cognitive Dysfunction - blood</subject><subject>Cognitive Dysfunction - drug therapy</subject><subject>Cognitive Dysfunction - epidemiology</subject><subject>Cognitive impairment</subject><subject>Dementia</subject><subject>Depression</subject><subject>Depression - drug therapy</subject><subject>Depression - epidemiology</subject><subject>Diagnosis</subject><subject>Donepezil</subject><subject>Elderly</subject><subject>Elderly people</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Geriatrics</subject><subject>Humans</subject><subject>Indans - therapeutic use</subject><subject>Late-life depression</subject><subject>Linear Models</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mild cognitive impairment</subject><subject>Miscellaneous</subject><subject>Mood disorders</subject><subject>Nervous system</subject><subject>Pathophysiology</subject><subject>Piperidines - therapeutic use</subject><subject>Psychiatry</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Time Factors</subject><issn>0022-3956</issn><issn>1879-1379</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><recordid>eNqNkk1v1DAQhiMEoqXwF5AvSFyy-CvOhkOltuJLqsQBOFuOM9mdxbGDnay0h_53HO3SAqeebMvPvPOO3ikKwuiKUabe7Va7MR3sFiOkFadMrBhbUSqfFOdsXTclE3XztDinlPNSNJU6K16ktKOU1pzJ58UZl7yhQtXnxd11NOjLDiLuoSMe5himGMYtWtIbO4VIHOzBJYKeODNB6bAH0sGYWycMnhjfERuGEFvsyIBueW08TlmP4DAajAP46T25Ii74DU5zh944kvLl8LJ41huX4NXpvCh-fPzw_eZzefv105ebq9vSqkZNJZdVJdedamsqWkEZGCmFqloKvZVWcMX6lucnF6ynYKlkvVAKqpo2rOq7RlwUl0fdcW4H6Gw2FI3TY8TBxIMOBvW_Px63ehP2WjScNUpmgbcngRh-zZAmPWCy4JzxEOakWSVZUyvVVI9Bs1G5Vout9RG1MaQUob93xKhegtY7_RC0XoLWjOkcdC59_fdE94V_ks3AmxNgkjWuj8ZbTA_cmirJqcrc9ZHLGcMeIepkEbyFLve0k-4CPsbN5X8i1qHH3PcnHCDtwhxz5nl2nbim-tuymMteMkGpkKIRvwFGieOd</recordid><startdate>20140201</startdate><enddate>20140201</enddate><creator>Diniz, Breno Satler</creator><creator>Reynolds, Charles F</creator><creator>Begley, Amy</creator><creator>Dew, Mary Amanda</creator><creator>Anderson, Stewart J</creator><creator>Lotrich, Francis</creator><creator>Erickson, Kirk I</creator><creator>Lopez, Oscar</creator><creator>Aizenstein, Howard</creator><creator>Sibille, Etienne L</creator><creator>Butters, Meryl A</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7QJ</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0653-1905</orcidid></search><sort><creationdate>20140201</creationdate><title>Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: A longitudinal study</title><author>Diniz, Breno Satler ; Reynolds, Charles F ; Begley, Amy ; Dew, Mary Amanda ; Anderson, Stewart J ; Lotrich, Francis ; Erickson, Kirk I ; Lopez, Oscar ; Aizenstein, Howard ; Sibille, Etienne L ; Butters, Meryl A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c696t-245548d6b703b301ea44365b0efc4c3261fb25b0231f0ec041f366e570915fd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult and adolescent clinical studies</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>BDNF</topic><topic>Biological and medical sciences</topic><topic>Brain-Derived Neurotrophic Factor - blood</topic><topic>Cognitive Dysfunction - blood</topic><topic>Cognitive Dysfunction - drug therapy</topic><topic>Cognitive Dysfunction - epidemiology</topic><topic>Cognitive impairment</topic><topic>Dementia</topic><topic>Depression</topic><topic>Depression - drug therapy</topic><topic>Depression - epidemiology</topic><topic>Diagnosis</topic><topic>Donepezil</topic><topic>Elderly</topic><topic>Elderly people</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Geriatrics</topic><topic>Humans</topic><topic>Indans - therapeutic use</topic><topic>Late-life depression</topic><topic>Linear Models</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mild cognitive impairment</topic><topic>Miscellaneous</topic><topic>Mood disorders</topic><topic>Nervous system</topic><topic>Pathophysiology</topic><topic>Piperidines - therapeutic use</topic><topic>Psychiatry</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Diniz, Breno Satler</creatorcontrib><creatorcontrib>Reynolds, Charles F</creatorcontrib><creatorcontrib>Begley, Amy</creatorcontrib><creatorcontrib>Dew, Mary Amanda</creatorcontrib><creatorcontrib>Anderson, Stewart J</creatorcontrib><creatorcontrib>Lotrich, Francis</creatorcontrib><creatorcontrib>Erickson, Kirk I</creatorcontrib><creatorcontrib>Lopez, Oscar</creatorcontrib><creatorcontrib>Aizenstein, Howard</creatorcontrib><creatorcontrib>Sibille, Etienne L</creatorcontrib><creatorcontrib>Butters, Meryl A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of psychiatric research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Diniz, Breno Satler</au><au>Reynolds, Charles F</au><au>Begley, Amy</au><au>Dew, Mary Amanda</au><au>Anderson, Stewart J</au><au>Lotrich, Francis</au><au>Erickson, Kirk I</au><au>Lopez, Oscar</au><au>Aizenstein, Howard</au><au>Sibille, Etienne L</au><au>Butters, Meryl A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: A longitudinal study</atitle><jtitle>Journal of psychiatric research</jtitle><addtitle>J Psychiatr Res</addtitle><date>2014-02-01</date><risdate>2014</risdate><volume>49</volume><spage>96</spage><epage>101</epage><pages>96-101</pages><issn>0022-3956</issn><eissn>1879-1379</eissn><coden>JPYRA3</coden><abstract>Abstract Changes in brain-derived neurotrophic factor (BDNF) level are implicated in the pathophysiology of cognitive decline in depression and neurodegenerative disorders in older adults. We aimed to evaluate the longitudinal association over two years between BDNF and persistent cognitive decline in individuals with remitted late-life depression and Mild Cognitive Impairment (LLD + MCI) compared to either individuals with remitted LLD and no cognitive decline (LLD + NCD) or never-depressed, cognitively normal, elderly control participants. We additionally evaluated the effect of double-blind, placebo-controlled donepezil treatment on BDNF levels in all of the remitted LLD participants (across the levels of cognitive function). We included 160 elderly participants in this study (72 LLD + NCD, 55 LLD + MCI and 33 never-depressed cognitively normal elderly participants). At the same visits, cognitive assessments were conducted and blood sampling to determine serum BDNF levels were collected at baseline assessment and after one and two years of follow-up. We utilized repeated measure, mixed effect models to assess: (1) the effects of diagnosis (LLD + MCI, LLD + NCD, and controls), time, and their interaction on BDNF levels; and (2) the effects of donepezil treatment (donepezil vs. placebo), time, baseline diagnosis (LLD + MCI vs. LLD + NCD), and interactions between these contrasts on BDNF levels. We found a significant effect of time on BDNF level ( p = 0.02) and a significant decline in BDNF levels over 2 years of follow-up in participants with LLD + MCI ( p = 0.004) and controls ( p = 0.04). We found no effect of donepezil treatment on BDNF level. The present results suggest that aging is an important factor related to decline in BDNF level. Clinicaltrials.gov Identifier: NCT00177671.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>24290367</pmid><doi>10.1016/j.jpsychires.2013.11.004</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-0653-1905</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3956 |
| ispartof | Journal of psychiatric research, 2014-02, Vol.49, p.96-101 |
| issn | 0022-3956 1879-1379 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3921964 |
| source | Applied Social Sciences Index & Abstracts (ASSIA); MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult and adolescent clinical studies Aged Aged, 80 and over Antidepressive Agents - therapeutic use BDNF Biological and medical sciences Brain-Derived Neurotrophic Factor - blood Cognitive Dysfunction - blood Cognitive Dysfunction - drug therapy Cognitive Dysfunction - epidemiology Cognitive impairment Dementia Depression Depression - drug therapy Depression - epidemiology Diagnosis Donepezil Elderly Elderly people Enzyme-Linked Immunosorbent Assay Female Geriatrics Humans Indans - therapeutic use Late-life depression Linear Models Longitudinal Studies Male Medical sciences Mild cognitive impairment Miscellaneous Mood disorders Nervous system Pathophysiology Piperidines - therapeutic use Psychiatry Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Time Factors |
| title | Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: A longitudinal study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T10%3A34%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brain-derived%20neurotrophic%20factor%20levels%20in%20late-life%20depression%20and%20comorbid%20mild%20cognitive%20impairment:%20A%20longitudinal%20study&rft.jtitle=Journal%20of%20psychiatric%20research&rft.au=Diniz,%20Breno%20Satler&rft.date=2014-02-01&rft.volume=49&rft.spage=96&rft.epage=101&rft.pages=96-101&rft.issn=0022-3956&rft.eissn=1879-1379&rft.coden=JPYRA3&rft_id=info:doi/10.1016/j.jpsychires.2013.11.004&rft_dat=%3Cproquest_pubme%3E1540234869%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1540234869&rft_id=info:pmid/24290367&rft_els_id=1_s2_0_S0022395613003439&rfr_iscdi=true |